Precigen reports third quarter 2022 financial results and progress of clinical programs

–   company will host virtual r&d event in early january 2023, timed to coincide with the 41st annual jp morgan healthcare conference , to showcase complete clinical trial data from phase 1 dose escalation and expansion cohorts of prgn-2012 adenoverse ™  immunotherapy in recurrent respiratory papillomatosis (rrp) – –   company to present two abstracts at the 64th american society of hematology (ash) annual meeting and exposition in december: prgn-3006 ultracar-t® phase 1 safety and efficacy data in acute myeloid leukemia (aml) and prgn-3007 ultracar-t phase 1/1b trial-in-progress in ror1-positive hematological and solid tumors – –   retired $144.0 million of outstanding convertible notes due in july 2023 resulting in $5.4 million in savings via the discount realized and interest savings – –   cash, cash equivalents, short-term investments and restricted cash totaled $153.8 million as of september 30, 2022 – germantown, md. , nov. 9, 2022 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2022 financial results and progress of clinical programs.
PGEN Ratings Summary
PGEN Quant Ranking